


# MPP's Expression of Interest and Sublicensing process


- MPP has an expression of interest process (EOI) for sublicensing IP it obtains from originators
- EOIs are to be submitted online on our website: <https://medicinespatentpool.org/what-we-do/expression-of-interest/>
- At the end of this webinar, the EOI system will be opened. EOIs can be submitted for licence to:
  - Bictegravir, TAF, TDF, emtricitabine, cobicistat, elvitegravir (Gilead)
  - Dolutegravir adult (ViiV Healthcare)
  - Lopinavir and ritonavir adult (Abbvie)
  - Daclatasvir (BMS)
- Two currently open calls for proposal on development oriented licences: sutezolid (TB) and ravidasvir (HCV)
- Objective: EOI is your proposal to use licensed IP to improve access to medicine
- The EOI process assesses:
  - Capacity, capability, readiness and willingness to
  - Develop, register for approval, manufacture and distribute
  - Appropriate APIs and formulations enabled by our licences and required in licensed countries (following guidelines)
- The process:
  - Rigorous, objective, standardized, quantified
  - Panel of evaluators
  - Decision makers are blinded

- Applicants encouraged to provide as much detail as possible for accurate assessment of their EOI
- All information kept strictly confidential
- Schedule:
  - EOI system opens: 13 Dec 2017
    - New applicants: need to register – generate a login/password
    - Trouble? Write to [eoimedicinespatentpool.org](mailto:eoimedicinespatentpool.org)
  - Q&As about using the EOI portal: 13-22 Dec 2017 and 8-31 Jan 2018 ([eoimedicinespatentpool.org](mailto:eoimedicinespatentpool.org))
  - EOI submission deadline: 31 Jan 2018
  - Q&As on EOI responses by MPP: submission date through end of evaluation
  - Communication with offer for licences (tentative): 30 April 2018
    - Sign & send scanned form agreements back: within 15 calendar days of offer
    - Hard copies soon after
    - Failure to sign within deadline may result in lapse of offer to license
  - Please ensure your legal has reviewed and cleared the licence agreement before you apply
    - Q&A on licence agreement: Dec 13-19 and 8-31 Jan 2018 ([eoimedicinespatentpool.org](mailto:eoimedicinespatentpool.org))



medicines  
patent  
pool

THE EOI PORTAL





MEDICINES PATENT POOL  
Expression of Interest

Username

Password

[Forgot password?](#)



medicines  
patent  
pool

## ACCOUNT CREATION

Welcome to the Medicines Patent Pool Expression of Interest system. Please create your account by filling in your information below.

User Information

This information will be used to sign-work you do on the ECI system.

Login:

Password:

Re-type your password:

Email:

Company Information

Company name:

Web address:

Physical address:

Zip Code:

City:

Country:

Telephone number (format: 00XXX XX XXX XXX):

- Link: : <http://eoi.medicinespatentpool.org>
- New applicants must create a login/password:
  - **Step 1:** Click 'Sign Up'
  - **Step 2:** Complete account creation questionnaire with required credentials
  - **Step 3:** Click 'Submit to MPP'. Once login request is approved, you will receive a notification by email

## YOUR EXPRESSION OF INTEREST

[CREATE A NEW EOI](#)

Drafts

Thu, 17 March 2016 22:39:51  
**Lopinavir, ritonavir (adult) - Lopinavir and ritonavir adult (AbbVie)**  
Status : draft

[EDIT THIS EOI](#) [DELETE THIS EOI](#)

Fri, 19 December 2014 09:40:41  
**Abacavir (Paediatric) - Atazanavir**  
Status : draft

[EDIT THIS EOI](#) [DELETE THIS EOI](#)

Awaiting validation

EOIs below have been submitted to the Medicines Patent Pool team. You can review them, but you will not be able to change any details.

In process

The Medicines Patent Pool team is reviewing the EOIs below. You will be notified at the right of any questions or requests for additional information.

Applications closed

## NOTIFICATIONS

There are no new notifications.

[SHOW HISTORY](#)

PLEASE, SELECT THE LICENCE AGREEMENT YOU ARE INTERESTED IN.

ABACAVIR (PAEDIATRIC)

ATAZANAVIR | [MPP-BMS Licence Agreement.zip](#)

DOLUTEGRAVIR | [MPP-ViiV Dolutegravir Licence Agreements.zip](#)

GILEAD LICENCE AGREEMENT | [MPP-Gilead-Sciences-Amended-Licence.pdf](#)

DRAFTS

Thu, 17 March 2016 22:39:51  
**Lopinavir, ritonavir (adult) -  
Lopinavir and ritonavir adult  
(AbbVie)**  
Status : *draft*

[EDIT THIS EOI](#)

[DELETE THIS EOI](#)

Fri, 19 December 2014 09:40:41  
**Abacavir (Paediatric) -  
Atazanavir**  
Status : *draft*

[EDIT THIS EOI](#)

[DELETE THIS EOI](#)

- To create a new EOI application, applicant can select from a list of available licences
- Applicant must fully fill in requested information including uploading necessary documents
- Can save form as draft until complete
- When application is complete, click 'submit to MPP'

- After EOI application is submitted, MPP may request further information/clarification from the applicant
- If this occurs, applicant will receive notification via email as well as a notification on the EOI portal dashboard
- Please respond in a thorough and timely manner



Please submit any questions on how to use the EOI portal to:

[eoimedicinespatentpool.org](mailto:eoimedicinespatentpool.org)